Title: Manfred Schmitt - Innovator in Cancer Treatment Methods
Introduction
Manfred Schmitt is an inventor based in München, Germany. He has contributed to the field of cancer treatment through his innovative methods. Although he currently holds no granted patents, his work has the potential to impact patient care significantly.
Latest Patent Applications
One of his notable patent applications is titled "Methods For Selecting Treatment Regimens And Predicting Outcomes In Cancer Patients." This invention relates to methods for determining a treatment regimen beyond the removal of tumor tissue for node-negative or node-positive breast cancer patients. The method involves measuring the levels of urokinase-type plasminogen activator (uPA) and plasminogen activator-1 (PAI-1) in a subject, preferably a tumor. Based on these values, the expected benefit, including disease-free survival and/or overall survival for the patient, can be predicted. High-risk subjects are identified by high levels of both uPA and PAI-1, high levels of uPA with low levels of PAI-1, or low levels of uPA with high levels of PAI-1. Treatment options for high-risk subjects include adjuvant CMF chemotherapy, adjuvant non-CMF chemotherapy, adjuvant endocrine therapy, adjuvant anthracyclin-containing chemotherapy, radiation therapy, and gene therapy. For low-risk subjects, treatment options may include no treatment, radiation, and adjuvant endocrine therapy.
Conclusion
Manfred Schmitt's innovative approach to cancer treatment showcases his dedication to improving patient outcomes. His work in developing methods for selecting treatment regimens highlights the importance of personalized medicine in oncology.